Drug Trial Radar · NCT06632262
A Phase 2 Clinical Study of ABSK061 and ABSK043
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Nov 30, 2029
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Conditions
- HER2-Gastric/Gastroesophageal Junction Cancer
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
- Solid Tumors
Interventions
ABSK061 + ABSK043Drug
Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
ABSK061+ABSK043 in combination with CAPOXDrug
Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose limited toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- To assess the tolerability of ABSK061 + ABSK043 in combination with CAPOX in patients with first-line gastric/gastroesophageal junction cancerTime frame: At the end of Cycle 1 (each cycle is 21 days)
- To assess the anti-tumor activity of ABSK061 + ABSK043 in combination with CAPOX as the primary endpoint of Progression-free survival (PFS) in first-line treatment of patients with metastatic/unresectable HER2-gastric/gastroesophageal junction cancerTime frame: up to 5 years
- To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable urothelial cancer with FGFR2/3 activating alteration or FGFR3 overexpression, with Objective response rate (ORR) as the primary endpointTime frame: up to 5 years
- To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with non-small cell lung cancer withFGFR2/3 activating alteration or overexpression as the primary endpointTime frame: up to 5 years
- To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable other advanced solid tumors with FGFR2/3 activatingon alteration or overexpression as the primary endpointTime frame: up to 5 years
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Changzhi People's Hospital
Changzhi, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, China · Not yet recruiting
The First Hospital of China Medical University
Hangzhou, China · Not yet recruiting
Zhejiang Provincial People'S Hospital
Hangzhou, China · Not yet recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China · Not yet recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China · Not yet recruiting
First Hospital of Shanxi Medical University
Xi'an, China · Not yet recruiting
Shanxi Cancer hospital (Shanxi Cancer institute)
Xi'an, China · Not yet recruiting
First Affiliated Hospital of Xiamen University
Xiamen, China · Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China · Not yet recruiting
Guizhou Provincial People'S Hospital
Guiyang, Guizhou, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Heibei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Hunan Central Hospital
Changsha, Hunan, China · Not yet recruiting
Jiangxi Cance Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China · Not yet recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
ZhongShan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Sichuang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.